Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 55154-7630

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 55154-7630). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (303c643b E390 4a6d Afc0 5fe86ae49e03 00)

Label for Atorvastatin Calcium Tablets USP 20 mg, film-coated, oral dosage form, packaged with 10 tablets. The label includes storage instructions to keep between 20°C to 25°C, with permissible excursions. It states prescription only use and advises dispensing with patient information leaflets. Manufactured by Apotex Inc. and distributed by Cardinal Health, with additional details and warnings noted.*

FDA Label Image

Bag Label (303c643b E390 4a6d Afc0 5fe86ae49e03 01)

Label for Atorvastatin Calcium Tablets USP 10 mg, film-coated oral tablets in a 10-tablet package. The label includes storage instructions, usage warnings, and distribution details, indicating the product is for prescription use only. Manufactured by Apotex Inc and labeled by Cardinal Health 107, LLC.*

FDA Label Image

Figure-01 (Figure 01)

A line chart comparing the cumulative incidence (%) over time (years) between Atorvastatin and Placebo groups. The chart shows two curves, one solid line for Atorvastatin and a dotted line for Placebo, with incidence increasing over 3.5 years. Statistical information including hazard ratio (HR=0.64) and p-value (p=0.0005) is displayed on the graph.*

FDA Label Image

Figure-02 (Figure 02)

A Kaplan-Meier survival curve comparing cumulative hazard percentages over time for Atorvastatin and placebo groups. The X-axis represents time to first primary endpoint through four years of follow-up, while the Y-axis shows the cumulative hazard percentage. The Atorvastatin group consistently has a lower cumulative hazard than the placebo group throughout the follow-up period.*

FDA Label Image

Figure-03 (Figure 03)

A line graph depicting the percentage of subjects experiencing a cardiovascular event over five years, comparing Atorvastatin 10 mg and 80 mg doses. The x-axis shows time to first major cardiovascular endpoint in years, and the y-axis shows the percentage of subjects. The graph includes a hazard ratio (HR 0.78) with confidence intervals and a p-value indicating statistical significance.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure diagram of atorvastatin calcium, showing the molecular arrangement of the active ingredient atorvastatin calcium in this prescription drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.